RecruitingNCT03529617
Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
60 participants
Start Date
Oct 19, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Treatment with L-AmB
- Admitted to an ICU or Hematology ward
Exclusion Criteria3
- DNR 2 or 3
- Pregnant or lactating women
- Previous documentation of intolerance/sensitivity to L-AmB
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERSample collection
Plasma, urine, BAL and ascitic fluid sample collection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03529617
Related Trials
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
NCT067336751 location
A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
NCT054698541 location
Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy
NCT037372921 location
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
NCT065007931 location
Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
NCT066521261 location